View in EDS

Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.

Saved in:
Bibliographic Details
Title: Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
Authors: Cortellini, Alessio1,2,3 (AUTHOR) a.cortellini@policlinicocampus.it, Garbo, Edoardo4 (AUTHOR), La Cava, Giulia1,2 (AUTHOR), Citarella, Fabrizio2 (AUTHOR), Santo, Valentina1,2,4 (AUTHOR), Brunetti, Leonardo1,2,3 (AUTHOR), Pinato, David J3,5 (AUTHOR), Naidoo, Jarushka6,7,8 (AUTHOR), Loza, Monica9 (AUTHOR), Genova, Carlo10,11 (AUTHOR), Gettinger, Scott12 (AUTHOR), Kim, So Yeon12 (AUTHOR), Jayakrishnan, Ritujith12 (AUTHOR), Zarif, Talal El12 (AUTHOR), Russano, Marco1 (AUTHOR), Pecci, Federica4 (AUTHOR), Di Federico, Alessandro4 (AUTHOR), Montrone, Michele13 (AUTHOR), Owen, Dwight H14,15 (AUTHOR), Signorelli, Diego16 (AUTHOR)
Source: Lung Cancer (01695002). Nov2025, Vol. 209, pN.PAG-N.PAG. 1p.
Database: Academic Search Ultimate
Description
ISSN:01695002
DOI:10.1016/j.lungcan.2025.108799